Related Experiment Videos

Management of cardiovascular complications in systemic lupus erythematosus

Carly Skamra, Rosalind Ramsey-Goldman

    International Journal of Clinical Rheumatology
    |March 23, 2010
    PubMed

    Insights

    Patients with systemic lupus erythematosus (SLE) face significantly higher cardiovascular disease (CVD) risks, especially younger women. This review explores multifactorial causes and management strategies for CVD in SLE patients.

    Area of Science:

    • Rheumatology
    • Cardiology
    • Immunology

    Background:

    • Systemic lupus erythematosus (SLE) is associated with a substantially increased risk of cardiovascular disease (CVD) compared to the general population.
    • This elevated risk is particularly pronounced in younger women with SLE, exhibiting over a 50-fold increased risk.
    • Subclinical atherosclerosis is more prevalent in SLE patients, as evidenced by various imaging techniques.

    Purpose of the Study:

    • To review the multifactorial causes of excess cardiovascular disease (CVD) and subclinical atherosclerosis in patients with systemic lupus erythematosus (SLE).
    • To discuss novel cardiovascular risk factors and SLE-specific variables contributing to CVD risk.
    • To examine risk factor modification and available treatment evidence for CVD in SLE, acknowledging the lack of specific randomized controlled trials.

    Main Methods:

    • Literature review of studies investigating cardiovascular disease (CVD) and subclinical atherosclerosis in patients with systemic lupus erythematosus (SLE).
    • Analysis of traditional and novel cardiovascular risk factors, including SLE-specific variables.
    • Evaluation of current evidence for risk factor modification and treatment strategies in SLE.

    Main Results:

    • Patients with SLE have a significantly higher risk of CVD and subclinical atherosclerosis.
    • Even after accounting for traditional Framingham risk factors, SLE patients exhibit a 7.5-fold greater excess risk of CVD.
    • The causality of increased CVD risk in SLE is multifactorial, involving both traditional and unique SLE-related factors.

    Conclusions:

    • Cardiovascular disease (CVD) poses a major threat to patients with systemic lupus erythematosus (SLE).
    • Management strategies for CVD risk factors in SLE are largely extrapolated from guidelines for other high-risk populations due to a lack of specific randomized controlled trials.
    • Further research and targeted interventions are needed to address the unique cardiovascular risks in SLE patients.

    Related Concept Videos

    Rheumatic Heart Disease III: Medical Management01:21

    Rheumatic Heart Disease III: Medical Management

    Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
    Rheumatic Heart Disease IV: Nursing Management01:20

    Rheumatic Heart Disease IV: Nursing Management

    AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
    Cardiomyopathy VI: Nursing Management01:29

    Cardiomyopathy VI: Nursing Management

    Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...